Drug screen for identifying an agent that modulates low density lipoprotein receptor adaptin-ligand binding
US6465196B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2001 |
| Grant date | Oct 15, 2002 |
| Priority date | — |
| Expiry date | Mar 13, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/044
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Low density lipoprotein receptor (LDRL) adaptin is a novel, key component of human cholesterol regulation, which provides a target for rational drug design and screening, therapeutic intervention, and diagnosis. Disclosed reagents include a variety of LDLR adaptin and LDLR adaptin PTB and CC domain compositions, including in vitro compositions comprising a natural human LDLR adaptin PTB domain and a ligand such as an NPXY (SEQ ID NO:7) peptide. These LDLR adaptin reagents are used, inter alia, in rational drug screening methods. The invention also provides polynucleotides encoding the subject LDLR adaptin polypeptides, including natural coding sequences, which may be used as probes or primers for detecting or amplifying LDLR adaptin genes and transcripts.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.